access and reimbursement

https://clarivate.com/life-sciences-healthcare/report/acremd0003-2017-biopharma-type-2-diabetes-access-and-reimbursement-us-2017/ Type 2 Diabetes | Access and Reimbursement | US | 2017 | Clarivate The type 2 diabetes market has become increasingly crowded, with therapies competing over preferential formulary placement as well as patient share. Using... access and reimbursement type diabetes us clarivate https://clarivate.com/life-sciences-healthcare/report/acreim0008-2016-biopharma-rheumatoid-arthritis-access-and-reimbursement-argentina-mexico-2016/ Rheumatoid Arthritis | Access and Reimbursement | Argentina/Mexico | 2016 | Clarivate Introduction Rheumatoid arthritis (RA) affects a significant percentage of Argentinian and Mexican populations and often requires the use of premium-priced... access and reimbursement rheumatoid arthritis argentina mexico clarivate https://clarivate.com/life-sciences-healthcare/report/acreon0014-2020-biopharma-non-small-cell-lung-cancer-access-and-reimbursement-us-2020/ Non-Small-Cell Lung Cancer | Access and Reimbursement | US | 2020 | Clarivate The high number of premium-priced non-small-cell lung cancer (NSCLC) therapies and the large number of NSCLC patients have resulted in a significant financial... small cell lung cancer access and reimbursement non https://clarivate.com/life-sciences-healthcare/report/acreim0030-2025-biopharma-psoriatic-arthritis-access-and-reimbursement-access-reimbursement-psoriatic-arthritis-us/ Psoriatic Arthritis - Access and Reimbursement - Access & Reimbursement - Psoriatic Arthritis (US)... The PsA therapy market is undergoing significant transformation with the emergence of new treatment options, intensifying competition for favorable payer... access and reimbursement psoriatic arthritis us https://clarivate.com/life-sciences-healthcare/report/acreon0035-2018-biopharma-immune-checkpoint-inhibitors-access-and-reimbursement-us-2018/ Immune Checkpoint Inhibitors | Access and Reimbursement | US | 2018 | Clarivate Immune checkpoint inhibitors have revolutionized the treatment of multiple oncology indications, but the high costs associated with these agents present... immune checkpoint inhibitors access and reimbursement us clarivate https://clarivate.com/life-sciences-healthcare/report/acrecg0034-2020-biopharma-epilepsy-access-and-reimbursement-us-2020/ Epilepsy | Access and Reimbursement | US | 2020 | Clarivate Despite the large number of currently marketed antiepileptic drugs (AEDs), important unmet needs remain for new therapies to treat refractory epilepsy and... access and reimbursement epilepsy us clarivate https://www.frontiersin.org/journals/medical-technology/articles/10.3389/fmedt.2023.1101476/full Frontiers | Access and reimbursement pathways for digital health solutions and in vitro diagnostic... Objectives: Digital therapeutics (DTx) are innovative solutions that use meaningful data to provide evidence-based decisions for the prevention, treatment, a... access and reimbursement digital health solutions https://clarivate.com/life-sciences-healthcare/report/acrecg0025-2017-biopharma-schizophrenia-access-and-reimbursement-depot-antipsychotic-use-us-2017/ Schizophrenia | Access and Reimbursement | Depot Antipsychotic Use | US | 2017 | Clarivate Despite the availability of multiple oral atypical antipsychotics in the United States, long-acting depot formulations of atypical antipsychotics offer a... access and reimbursement use us schizophrenia depot antipsychotic https://clarivate.com/life-sciences-healthcare/report/acreim0011-2016-biopharma-spondyloarthritis-access-and-reimbursement-us-2016/ Spondyloarthritis | Access and Reimbursement | US | 2016 | Clarivate The U.S. therapy market for the SpA indications PsA, AS, and nr-AxSpA is becoming increasingly crowded as new biologics and SMIs offering novel MOAs enter the... access and reimbursement spondyloarthritis us clarivate https://clarivate.com/life-sciences-healthcare/report/acreon0018-2017-biopharma-breast-cancer-access-and-reimbursement-the-influence-of-value-assessment-models-on-clinical/ Breast Cancer | Access and Reimbursement |The influence of value assessment models on clinical... Facing a dramatic rise in expenditures for cancer therapies, U.S. healthcare payers are increasingly assessing the value of drugs relative to their prices,... access and reimbursement https://clarivate.com/life-sciences-healthcare/report/acrecv0001-2016-biopharma-heart-failure-access-and-reimbursement-chronic-heart-failure-us-2016/ Heart Failure | Access and Reimbursement | Chronic Heart Failure | US | 2016 | Clarivate The chronic heart failure therapy market is crowded and dominated by generics. In 2015 in the United States, the first new branded agents in more than 15 years... access and reimbursement heart failure chronic us clarivate https://clarivate.com/life-sciences-healthcare/report/acremd0003-2020-biopharma-type-2-diabetes-access-and-reimbursement-us-2020/ Type 2 Diabetes | Access and Reimbursement | US | 2020 | Clarivate The treatment of type 2 diabetes places a significant economic burden on the U.S. healthcare system. Given the intense competition between antidiabetic... access and reimbursement type diabetes us clarivate https://clarivate.com/life-sciences-healthcare/report/acreim0002-2016-biopharma-asthma-access-and-reimbursement-us-2016/ Asthma | Access and Reimbursement | US | 2016 | Clarivate The U.S. asthma therapy market has long been dominated by several effective and well-established treatments, including inhaled and oral therapies, but... access and reimbursement asthma us clarivate

Robuta